Diligence memo · auto-generated · as of July 2, 2026
Nkarta, Inc.
Nkarta, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Nkarta, Inc. operates in Biotechnology, based in SOUTH SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nkarta, Inc. has raised $44M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $44M on 2019-08-27.
Most recent recorded round closed around 2019-08-27.
Valuation (modeled)modeled
Provath models Nkarta, Inc. at approximately $1.8B (range $136M–$4.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.93× the median modeled value of Series C Biotechnology companies in 2019–2021 (120 peers) — value vs value, same stage and era. Within the normal band (93% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 6.8 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 80% of Biotechnology peers (4293 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Stem Biotech LLC, Kinnate Biopharma Inc., Arcutis Biotherapeutics, Inc., DNA Research INST LLC, M3 Biotechnology, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.